Edition:
United States

Axsome Therapeutics Inc (AXSM.OQ)

AXSM.OQ on NASDAQ Stock Exchange Global Market

2.55USD
20 Apr 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.55
Open
$2.55
Day's High
$2.60
Day's Low
$2.50
Volume
12,937
Avg. Vol
56,493
52-wk High
$6.45
52-wk Low
$2.05

Latest Key Developments (Source: Significant Developments)

Axsome Therapeutics Reports Q4 Loss Per Share $0.31
Wednesday, 7 Mar 2018 07:00am EST 

March 7 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 LOSS PER SHARE $0.31.AXSOME THERAPEUTICS - BELIEVES CASH AT DEC 31, 2017 TO BE SUFFICIENT TO FUND ANTICIPATED OPERATIONS INTO Q3 2019.AT DECEMBER 31, 2017, AXSOME HAD $34.0 MILLION OF CASH COMPARED TO $36.6 MILLION OF CASH AT DECEMBER 31, 2016.  Full Article

Axsome Collaborates With A Nicotine Addiction Research Center For Phase 2 Trial Of AXS-05 In Smoking Cessation
Thursday, 14 Dec 2017 07:00am EST 

Dec 14 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS COLLABORATES WITH WORLD-LEADING NICOTINE ADDICTION RESEARCH CENTER FOR PHASE 2 TRIAL OF AXS-05 IN SMOKING CESSATION.AXSOME THERAPEUTICS - ‍ENTERED RESEARCH COLLABORATION WITH DUKE UNIVERSITY TO EVALUATE AXS-05 IN A PHASE 2 CLINICAL TRIAL IN SMOKERS ATTEMPTING TO QUIT​.AXSOME THERAPEUTICS INC - ‍PHASE 2 TRIAL INITIATION ANTICIPATED IN Q1 OF 2018 FOR AXS-05​.  Full Article

Sabby Management Reports A 5.52 Percent Passive Stake In Axsome Therapeutics
Monday, 4 Dec 2017 09:58am EST 

Dec 4 (Reuters) - Axsome Therapeutics Inc ::SABBY MANAGEMENT, LLC REPORTS A 5.52 PERCENT PASSIVE STAKE IN AXSOME THERAPEUTICS INC AS OF DEC 1 - SEC FILING.  Full Article

Axsome Therapeutics Announces AXS-07 For The Treatment Of Migraine
Tuesday, 28 Nov 2017 07:00am EST 

Nov 28 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS ANNOUNCES AXS-07 FOR THE TREATMENT OF MIGRAINE.AXSOME THERAPEUTICS INC - ‍PHASE 3 TRIAL ANTICIPATED IN 2018​.AXSOME THERAPEUTICS INC - AXS-07 HAS ‍POTENTIAL FOR "SUPERIOR" EFFICACY AS COMPARED TO CURRENT TREATMENTS​.AXSOME THERAPEUTICS INC - ‍U.S. FDA PRE-INVESTIGATIONAL NEW DRUG APPLICATION​ MEETING WRITTEN GUIDANCE RECEIVED.  Full Article

Axsome Therapeutics reports Q3 loss per share $0.27
Wednesday, 8 Nov 2017 07:00am EST 

Nov 8 (Reuters) - Axsome Therapeutics Inc :Axsome Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.27.Axsome Therapeutics Inc - ‍Believes its cash as of Sept. 30, 2017 will be sufficient to fund anticipated operations into Q1 of 2019​.  Full Article

Axsome Therapeutics says ‍interim efficacy analysis of phase 3 create-1 trial of AXS-02 in complex regional pain syndrome expected year-end 2017​
Thursday, 7 Sep 2017 07:00am EDT 

Sept 7 (Reuters) - Axsome Therapeutics Inc :Axsome Therapeutics - ‍interim efficacy analysis of phase 3 create-1 trial of AXS-02 in complex regional pain syndrome (CRPS) is expected year-end 2017​.Axsome Therapeutics Inc - ‍interim analysis results for Coast-1 are now also expected late December 2017 to early January 2018​.  Full Article

Axsome Therapeutics reports Q2 loss per share $0.30
Wednesday, 9 Aug 2017 07:00am EDT 

Aug 9 (Reuters) - Axsome Therapeutics Inc :Axsome Therapeutics reports second quarter 2017 financial results.Q2 loss per share $0.30.Q2 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.Axsome Therapeutics Inc - cash as of June 30, will be sufficient to fund anticipated operations, based on its current operating plans, into Q1 of 2019​.  Full Article

Axsome Therapeutics announces AXS-06 meets primary endpoint in phase 1 clinical trial
Tuesday, 25 Jul 2017 07:00am EDT 

July 25 (Reuters) - Axsome Therapeutics Inc :Axsome Therapeutics announces AXS-06 (moseic meloxicam and esomeprazole) meets primary endpoint in phase 1 clinical trial.Axsome Therapeutics Inc - ‍primary endpoint met with 9 times faster time to maximum plasma concentration tmax of meloxicam versus mobic​.Says ‍received, from U.S. FDA, pre-ind written guidance on a proposed clinical developmental plan for AXS-06​.Says ‍believes that AXS-06 is phase 3-ready​.Axsome Therapeutics-‍look forward to further development of AXS-06 and to a data readout for AXS-02 in complex regional pain syndrome anticipated in Q4​.Axsome Therapeutics Inc - ‍AXS-06 was well tolerated with reported adverse events being similar across three treatment arms​.Says ‍there were no serious adverse events in study​.  Full Article

Axsome Therapeutics initiates Phase 2/3 trial of AXS-05 for Alzheimer’s disease agitation
Monday, 17 Jul 2017 07:00am EDT 

July 17 (Reuters) - Axsome Therapeutics Inc :Axsome Therapeutics initiates Phase 2/3 trial of AXS-05 for Alzheimer’s disease agitation.  Full Article

Axsome appoints John Golubieski as CFO
Thursday, 6 Jul 2017 07:00am EDT 

July 6 (Reuters) - Axsome Therapeutics Inc ::Axsome Therapeutics appoints John Golubieski as chief financial officer.Appointment of John Golubieski as chief financial officer, effective August 4, 2017.Axsome Therapeutics Inc - announced appointment of John Golubieski as chief financial officer, effective August 4, 2017.  Full Article

BRIEF-Axsome Therapeutics Announces First Patient Enrolled In Phase 2 Clinical Trial Of AXS-05 In Smoking Cessation

* AXSOME THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2 CLINICAL TRIAL OF AXS-05 IN SMOKING CESSATION Source text for Eikon: Further company coverage: